Oxford Biomedica named as winner of The Oxford Science Park Innovation Award 2019

Leading gene therapy manufacturer recognised as part of Oxfordshire Business Awards Oxford, UK, June 18 2019 - Its work on life-changing treatments for serious diseases has earned Oxford Biomedica, a leading gene and cell therapy group, The Oxford Science Park Innovation Award 2019.

Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK, announce strategic collaboration

Psychiatry Consortium to address unmet patient needs

CEO Update | Monday 17 June

Today, the BIA is pleased to publish a new report, ‘Life sciences: Catalysing investment and growth”. which sets out how our sector is driving investment and growth across the UK and makes the case for increased cost-effective public investment in the sector. The report aims to inform the Government, UKRI and other policy makers as they prepare for the forthcoming Spending Review and develop an R&D roadmap to reach 2.4% R&D target.

Video of the week | How Engineers Move Medicine Around The World

Medicines have complex storage and transportation needs, and getting medicines to remote locations requires lots of planning, clever engineering and infrastructure. Check out this video from SciShow on YouTube to find out more about how medicines are transported around the world. 

Bringing the benefits of cutting-edge mass spectrometry technologies to UK SMEs

Medicines Discovery Catapult and Waters partner to support UK medicines discovery with advanced technology solutions.

Why investors trust their gut about the human microbiome

FROM RESULTS HEALTHCARE The increasing popularity of the human microbiome in biotech has become a source of scientific and investor excitement in recent years. Microbiomes, or the genes of a community of microbial cells (or microbiota) which the body is host to, have unexpected benefits and implications for overall health, from regulating the immune system, to influencing conditions such as obesity, diabetes, cancer and aging. While it is in the gut that humans have the most diverse and densely populated microbiota, their influence and presence in other parts of the body has made the microbiome comparable to “a newly discovered organ” and a new route for therapeutic intervention, leading to a wave of start-ups and IPOs in the field.

Ligand subsidiary Vernalis and PhoreMost Limited announce drug discovery collaboration for novel oncology target

San Diego, USA and Cambridge, UK, 12 June, 2019: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

Labouring the point: How biotech should engage with the Labour Party

There can have been few moments when the political landscape has looked more uncertain, with polls fluctuating wildly, leadership contests in two separate parties and a looming hard deadline for Brexit. But while the machinations of the Conservative Party leadership race rumble on, it is also important not to forget that over on the Opposition benches, new policy is being formed which has a decent chance of being implemented in some form after the next general election. While current opinion polls suggest that the electorate may give many of their votes to the Liberal Democrats or the recently formed Brexit Party, a significant chunk remain with Labour. With Labour’s narrow win in Peterborough by-election fresh in everyone’s minds, it is clear that the party is still in the running.

CEO Update | Tuesday 11 June 2019

Many congratulations to BIA Chair, Dr Jane Osbourn who has been awarded an OBE in the Queen’s birthday honours announced at the weekend. Jane is a true pioneer in our sector, who not only has pioneered world-class research and contributed to blockbuster discoveries but is a passionate advocate for the UK life sciences sector. For me, Jane’s greatest qualities are her abilities to communicate and lead, she has and always will be a trailblazer in our sector and I’m delighted that she has received this award. In Westminster the Conservative leadership contest to replace Theresa May is underway and we have produced a life sciences focused guide to the runners and riders which is available here.

World leading antibody scientist Dr Jane Osbourn awarded OBE in Queen’s Honours

Dr Jane Osbourn, Vice-President of Research and Development at AstraZeneca and Chair of the UK BioIndustry Association (BIA) has been made an Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours list.